Probiotics in the Prevention of Complications After Colorectal Surgery

NCT ID: NCT02313519

Last Updated: 2014-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Based on the need of large-scale, trials to explore the use of probiotics to reduce post-operative complication rate, a randomized controlled trial is designed to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is reduction of post-operative complications after 30 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Major colorectal surgery, i.e. surgery involving a wide colon resection and/or a very low anastomosis, remains problematic, despite great advances in medico-pharmaceutical treatment, improvement in surgical techniques, and sophisticated postoperative management. Such surgery is still accompanied by an unacceptably high morbidity of 15% to 23.2% leading to an increase in the number of ventilatory support days, prolongation of total hospital stay, significantly higher medical costs, patient suffering, and, unfortunately mortality. Worse than this, nowadays, infections and sepsis are by far the most common morbidities, either as initial cause or as a consequence of another complication, such as anastomotic leakage. Ongoing clinical studies have reported probiotic therapies to be beneficial in elective surgery cases, since they have been shown to successfully modulate the GI flora in a plethora of medical settings and in critically ill and trauma patients. More precisely, recent randomized controlled studies and meta-analyses in elective surgery and abdominal surgery patients have demonstrated that the perioperative use of probiotics is safe and reduces both the incidence of postoperative wound infections, sepsis, post-operative pneumonia and other infections, and the necessary duration of hospital stay and length of antibiotic therapy. However, there exist few controlled, large-scale, trials comparing the current standard treatment with the probiotic concept and showing the superiority of the latter in colonic surgery with regard to a reduced complication rate. Therefore, the investigators decided to conduct a randomized controlled trial to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is to evidence a reduction in 30-day infectious, surgery-related morbidity: any surgical site infection; organ specific infections; systemic infections and anastomotic leakage. Minor objectives related to the reduction in other non-infectious complications, as well as the assessment of outcome indicators such as the number of days in postoperative ileus, on mechanical ventilation, stay in ICU, total hospitalization and mortality in the 30-day post-operative period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Complications

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Infections anastomotic leakage

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Glucose powder

Probiotics

Capsules containing Lactobacillus acidophilus LA-5 \[1.75x10\^9 cfu\], Lactobacillus plantarum \[0.5x10\^9 cfu\], Bifidobacterium lactis BB-12 \[1.75x10\^9cfu\], and Saccharomyces boulardii \[1.5x10\^9\] per capsule. One capsule is given every 12 hours for 15 days

Group Type ACTIVE_COMPARATOR

Probiotics

Intervention Type DIETARY_SUPPLEMENT

Probiotics are prepared in capsule form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotics

Probiotics are prepared in capsule form

Intervention Type DIETARY_SUPPLEMENT

Placebo

Glucose powder

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lactobacillus, Bifidobacterium and Saccharomyces boulardii Placebo capsules

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Acceptable nutritional status and programmed for open surgery for colorectal cancer.
* Operation by the same consultant either as surgeon or as the primary assistant.

Exclusion Criteria

* Inability to provide written informed consent
* The need only for emergency or palliative surgery
* American Society of Anaesthesiologists (ASA) class of IV
* Pregnancy or lactation
* Inflammatory bowel disease
* Use of antibiotics during the last 10 days before surgery
* Recent steroid therapy or preoperative neoadjuvant chemotherapy or radiotherapy
* Pre-existing signs of bacterial \[white cell count, body temperature\] or viral infection \[hepatitis B or C, human immunodeficiency virus, cytomegalovirus\].
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aristotle University Of Thessaloniki

OTHER

Sponsor Role collaborator

Evangelos J. Giamarellos-Bourboulis, M.D.

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Evangelos J. Giamarellos-Bourboulis, M.D.

Associate Professor of Medicine

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Katerina Kotxampassi, MD, PhD

Role: STUDY_CHAIR

AXEPA University of Thessaloniki, 1st Department of Propedeutic Surgery, Thessaloniki, Greece

Evangelos Giamarellos-Bourboulis, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Athens, 4th Department of Internal Medicine, Athens, Greece

References

Explore related publications, articles, or registry entries linked to this study.

Giamarellos-Bourboulis EJ, Bengmark S, Kanellakopoulou K, Kotzampassi K. Pro- and synbiotics to control inflammation and infection in patients with multiple injuries. J Trauma. 2009 Oct;67(4):815-21. doi: 10.1097/TA.0b013e31819d979e.

Reference Type BACKGROUND
PMID: 19820590 (View on PubMed)

Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J Surg. 2006 Oct;30(10):1848-55. doi: 10.1007/s00268-005-0653-1.

Reference Type BACKGROUND
PMID: 16983476 (View on PubMed)

Kotzampassi K, Stavrou G, Damoraki G, Georgitsi M, Basdanis G, Tsaousi G, Giamarellos-Bourboulis EJ. A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study. World J Surg. 2015 Nov;39(11):2776-83. doi: 10.1007/s00268-015-3071-z.

Reference Type DERIVED
PMID: 25894405 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LACT002

Identifier Type: -

Identifier Source: org_study_id